NewLink Genetics Corp (NASDAQ:NLNK) shares saw strong trading volume on Friday . 855,837 shares changed hands during mid-day trading, an increase of 81% from the previous session’s volume of 471,750 shares.The stock last traded at $1.79 and had previously closed at $1.73.
Several equities analysts recently issued reports on the company. Zacks Investment Research downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. ValuEngine downgraded NewLink Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday. Robert W. Baird cut their target price on NewLink Genetics from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, February 28th. Finally, Bank of America downgraded NewLink Genetics from a “neutral” rating to an “underperform” rating in a research report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $4.40.
The stock has a market cap of $64.12 million, a PE ratio of -1.24 and a beta of 1.79.
A number of large investors have recently bought and sold shares of NLNK. Paloma Partners Management Co purchased a new stake in NewLink Genetics in the fourth quarter valued at $30,000. Pennsylvania Trust Co purchased a new stake in NewLink Genetics in the first quarter valued at $48,000. Virtu Financial LLC purchased a new stake in NewLink Genetics in the first quarter valued at $60,000. Rhumbline Advisers boosted its holdings in NewLink Genetics by 41.4% in the fourth quarter. Rhumbline Advisers now owns 40,387 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 11,830 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in NewLink Genetics in the fourth quarter valued at $83,000. 34.54% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “NewLink Genetics (NLNK) Sees Unusually-High Trading Volume” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://weekherald.com/2019/05/03/newlink-genetics-nlnk-sees-unusually-high-trading-volume.html.
About NewLink Genetics (NASDAQ:NLNK)
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
See Also: Why do commodities matter?
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.